SLC5A2 and chronic kidney disease: Empagliflozin [132], canagliflozin [133] and sotagliflozin [134] have been reported to reduce the risk of adverse events in patients with CKD and diabetes by inhibiting sodium-glucose cotransporter 2 (SGLT2), supporting the potential use of sodium-glucose cotransporter 2 inhibitors combined with other drugs in the treatment of CKD and diabetes.